Clearmind Medicine Announces $1 Million Convertible Promissory Note Financing

On June 12, 2026, Clearmind Medicine Inc. entered into an agreement with CLA Investors to issue and sell convertible promissory notes in the aggregate principal amount of $1,000,000. This transaction is part of a previously established securities purchase agreement (SPA) dated September 17, 2025, which allows for the issuance of up to $10,000,000 in promissory notes. The current $1,000,000 issuance will be sold at a 10% discount, resulting in an aggregate purchase price of $900,000 in cash. In connection with this specific funding round, the parties agreed to exceed the standard quarterly limit and amended the floor price for the conversion price formula to $1.875 per common share. The investors involved in this tranche are L.I.A. Pure Capital Ltd. and Capitalink Ltd., each purchasing $500,000 in principal. The transaction is expected to close on or about June 14, 2026. The proceeds are intended to support the company's ongoing operations and development initiatives.